脊椎関節炎治療薬の世界市場機会分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 14
1.2 List of Figures 17
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 19
2.3 Upcoming Related Reports 19
3 Disease Overview 20
3.1 Etiology and Pathophysiology 20
3.1.1 Etiology 20
3.1.2 Pathophysiology 21
3.2 Symptoms 22
3.2.1 Ankylosing Spondylitis 22
3.2.2 Non-radiographic Axial Spondyloarthritis 24
4 Epidemiology 25
4.1 Risk Factors and Comorbidities 27
4.2 Global Trends 28
4.2.1 US 31
4.2.2 5EU 31
4.2.3 Japan 32
4.3 Forecast Methodology 32
4.3.1 Sources Used for Diagnosed Prevalence of AS 35
4.3.2 Sources Used for Diagnosed Prevalence of Nr-axSpA 38
4.3.3 Sources Used for the Prevalence of HLA-B27 Seropositivity in Diagnosed AS 39
4.3.4 Sources Not Used 40
4.3.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS — Base Scenario 41
4.3.6 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA — Base Scenario 43
4.3.7 Forecast Assumptions and Methods, HLA-B27 Seropositivity in Diagnosed AS 45
4.3.8 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS — Alternative Scenario 45
4.3.9 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA — Alternative Scenario 46
4.4 Epidemiological Forecast for AS (2014-2024) — Base Scenario 46
4.4.1 Diagnosed Prevalent Cases of AS 46
4.4.2 Age-Specific Diagnosed Prevalent Cases of Ankylosing Spondylitis 48
4.4.3 Sex-Specific Diagnosed Prevalent Cases of AS 49
4.4.4 Age-Standardized Diagnosed Prevalence of AS 51
4.4.5 Diagnosed Prevalent Cases of Nr-axSpA 52
4.4.6 Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases 54
4.5 Epidemiological Forecast for AS (2014-2024) — Alternative Scenario 57
4.5.1 Diagnosed Prevalent Cases of AS 57
4.5.2 Diagnosed Prevalent Cases of Nr-axSpA 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast Insight 60
4.6.2 Limitations of the Analysis 61
4.6.3 Strengths of the Analysis 61
5 Current Treatment Options 63
5.1 Overview 63
5.2 Product Profiles — Major Brands 65
5.2.1 Enbrel (etanercept) 65
5.2.2 Humira (adalimumab) 69
5.2.3 Remicade (infliximab) 73
5.2.4 Simponi (golimumab) 77
5.2.5 Cimzia (certolizumab pegol) 82
5.2.6 NSAIDs 86
5.2.7 Biosimilars 92
5.2.8 Other Therapies 99
6 Unmet Needs Assessment and Oppportunity Analysis 100
6.1 Overview 100
6.2 Lack of Awareness 101
6.2.1 Unmet Need 101
6.2.2 Gap Analysis 103
6.2.3 Opportunity 105
6.3 Standardization of Diagnosis and Early Treatment 105
6.3.1 Unmet Need 105
6.3.2 Gap Analysis 107
6.3.3 Opportunity 108
6.4 Drugs With Novel MOAs 109
6.4.1 Unmet Need 109
6.4.2 Gap Analysis 110
6.4.3 Opportunity 111
6.5 Recognition of Nr-axSpA 111
6.5.1 Unmet Need 111
6.5.2 Gap Analysis 113
6.5.3 Opportunity 114
7 R&D Strategies 115
7.1 Overview 115
7.1.1 Life-Cycle Management Strategies: Expansion from Key Autoimmune Indications 115
7.1.2 Life-Cycle Management Strategies: Expansion into Nr-axSpA 117
7.1.3 Development of New Formulations and Drug Delivery Methods 118
7.2 Clinical Trial Design 119
7.2.1 Ankylosing Spondylitis 119
7.2.2 Non-radiographic Axial Spondyloarthritis 123
7.2.3 Future Clinical Trials 124
8 Pipeline Assessment 126
8.1 Overview 126
8.2 Promising Drugs in Clinical Development 126
8.2.1 Cosentyx (Secukinumab) 126
8.2.2 Stelara (ustekinumab) 134
8.2.3 Otezla (apremilast) 140
8.3 Additional Drugs in Development for AS 145
9 Pipeline Valuation Analysis 149
9.1 Clinical Benchmarking of Key Pipeline Drugs 149
9.2 Commercial Benchmark of Key Pipeline Drugs 150
9.3 Competitive Assessment 152
9.4 Top Line Ten Year Forecast 154
9.4.1 US 160
9.4.2 5EU 162
9.4.3 Japan 163
10 Appendix 164
10.1 Abbreviations 164
10.2 Bibliography 168
10.3 Methodology 185
10.4 Forecasting Methodology 185
10.4.1 Diagnosed Patients 185
10.4.2 Percent Drug-Treated Patients 186
10.4.3 Drugs Included in Each Therapeutic Class 186
10.4.4 Launch and Patent Expiry Dates 187
10.4.5 General Pricing Assumptions 187
10.4.6 Individual Drug Assumptions 189
10.4.7 Generic Erosion 193
10.4.8 Pricing of Pipeline agents 193
10.5 Physicians and Specialists Included in this Study 194
10.6 Primary Research – Prescriber Survey 195
10.7 About the Authors 196
10.7.1 Author 196
10.7.2 Therapy Area Director 196
10.7.3 Epidemiologist 197
10.7.4 Global Head of Healthcare 197
10.8 About GlobalData 198
10.9 Disclaimer 198